Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are one of the main pillars of cancer therapy. Since other studies such as clinical trial and retrospective study have limitations for detecting the immune-related adverse events (irAEs) characterized by unpredictable onset, nonspecific symptoms and wide clinical spectrum, we aimed to identify the incidence of irAEs and to detect and evaluate the signals using real-world data.

Methods

Cancer patients treated with anticancer medications were analyzed using the nationwide health insurance claims database of South Korea from 2017 to 2019, and Clinical Data Warehouse (CDW) database of Asan Medical Center (AMC), a tertiary referral hospital, from 2012 to 2019. AEs of ICI users were compared with those of non-ICI anticancer medication

SUBMITTER: Kim EJ 

PROVIDER: S-EPMC10854742 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature